July 17, 2017

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CRISPR Therapeutics

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, today announced a research collaboration to explore the combination of each company’s proprietary technologies to develop novel T cell therapies.

Neon Logo

“Neon Therapeutics is committed to employ leading technologies, including CRISPR/Cas9, to improve the quality of our cell therapy approaches,” said Richard Gaynor, MD, president of research and development at Neon Therapeutics. “This collaboration will explore gene-based technologies from CRISPR Therapeutics with our expertise in neoantigen science and T cell biology.”

“We look forward to applying our proprietary CRISPR/Cas9 technologies in a variety of ways to generate potent T cell therapies directed against neoantigens. This collaboration with Neon Therapeutics supplements our internal efforts in immuno-oncology and broadens the spectrum of approaches we are able to explore,” said Samarth Kulkarni, president and chief business officer of CRISPR Therapeutics.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Dr. Emmanuelle Charpentier.  CRISPR Therapeutics is headquartered in Basel, Switzerland, with offices in London, United Kingdom, and R&D operations in Cambridge, Massachusetts.  For more information, please visit www.crisprtx.com.

About Neon Therapeutics 
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.  A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens.  Neon’s lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, and is in multiple clinical trials.  For more information, please visit www.neontherapeutics.com.

Source: http://ir.crisprtx.com/phoenix.zhtml?c=254376&p=irol-newsArticle&ID=2285321